Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study

Instructions

Click the REGISTER button to take the posttest
Click here to return to the JCP CME article 

Overview

Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.


Read the whole article at psychiatrist.com here: 
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study 

© Copyright 2022 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists 

Learning Objectives

After completing this educational activity, you should be able to understand which SUDs and other psychiatric patient subgroups may be more susceptible to severe COVID-19 infections and outcomes and better direct needed medical attention to these patients.

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
08/29/2022
Activity expires: 
10/31/2023
Cost:
$0.00

CME Objective

After studying this article, you should be able to:

  • Understand which SUDs and other psychiatric patient subgroups may be more susceptible to severe COVID-19 infections and outcomes and better direct needed medical attention to these patients.

Statement of Need and Purpose

Given the still-recent advent of the COVID-19 pandemic, information about the impact of the disease is still evolving. Factors that make some individuals more susceptible to severe illness and hospitalization have begun to emerge, including medical conditions (eg, asthma, heart disease, diabetes) and markers of poor overall health (eg, obesity and hypertension) as well as the presence of psychiatric disorders. Among mental illnesses, substance use disorders (SUDs) are highly prevalent. Although the presence of SUDs has been shown to lead to poorer treatment outcomes for medical illnesses, the specific impact of SUDs on COVID-19 outcomes has not been systematically studied. Given the high prevalence of both COVID-19 and SUDs and the need to direct medical attention to especially vulnerable patient populations, mental health practitioners need information about the difference in COVID-19 outcomes between individuals with SUDs and those without SUDs, specific SUDs that are more likely than others to affect COVID-19 outcomes, whether different SUDs affect different outcomes specifically, and whether the presence of other psychiatric disorders mediate the effect of SUDs on COVID-19 outcomes. Clarifying the effects of individual SUDs on COVID-19 outcomes, as well as ways in which other psychiatric disorders may mediate these effects, would allow appropriate medical attention and targeting of vaccination efforts to be directed to these especially susceptible patient groups.

Release, Expiration, and Review Dates

This educational activity was published in August 2022 and is eligible for AMA PRA Category 1 Credit™ through October 31, 2023. 

Unlabeled and Investigational Usage

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Funding/support

There was no specific funding for this study. 

Disclaimer

The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of NIH or any federal agency.

Previous presentation

Poster presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; October 27–29, 2021.

Faculty

Divya Ramakrishnan, BS
Yale University School of Medicine, New Haven, Connecticut

Soundari Sureshanand, MS
Yale Center for Clinical Investigations, Joint Data Analytics Team, New
Haven, Connecticut

Brian Pittman, MS
Department of Psychiatry, Yale University School of Medicine, New
Haven, Connecticut

Rajiv Radhakrishnan, MBBS, MD
Department of Psychiatry, Yale University School of Medicine, New
Haven, Connecticut

Financial Disclosure 

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past 3 years, Marlene P. Freeman, MD, Editor in Chief, has received research funding from JayMac and Sage; has been a member of the Independent Data Safety and Monitoring Committee for Janssen (Johnson &  Johnson), Novartis, and Neurocrine; and has served on advisory boards for Eliem and Sage. As an employee of Massachusetts General Hospital (MGH), Dr Freeman works with the MGH National Pregnancy Registry, which receives funding from Alkermes, Aurobindo, AuroMedics, Johnson & Johnson/Janssen, Otsuka, Sage, Sunovion, Supernus, and Teva, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. Dr Freeman has also received royalties through MGH for the Massachusetts General Hospital Female Reproductive Lifecycle and Hormones Questionnaire.No member of the CME Institute staff reported any relevant personal financial relationships.

Dr Radhakrishnan is supported by the Dana Foundation David Mahoney program and CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), components of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. He has received research support from Neurocrine Biosciences and GW Pharmaceuticals. Ms Ramakrishnan, Ms Sureshanand, and Mr Pittman have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses.